- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
ProQR Completes Patient Dosing for QR-010 Phase 1b Trial
ProQR Therapeutics N.V. announced it completed the dosing of cystic fibrosis patients in its Phase 1b clinical trial of QR-010.
ProQR Therapeutics N.V. (NASDAQ:PRQR) announced it completed the dosing of cystic fibrosis patients in its Phase 1b clinical trialĀ of QR-010.
As quoted in the press release:
About the PQ-010-01 Phase 1b Clinical Trial
The PQ-010-001 study is a Phase 1b, 28-day, randomized, double-blind, placebo-controlled safety and tolerability trial, conducted in patients that have cystic fibrosis (CF) due to two copies of the F508del mutation (homozygotes). A total of 4 dose levels were studied: 6.25, 12.5, 25 and 50mg of QR-010 in solution per dose administered via inhalation. The study design consisted of 8 cohorts of 8 patients for a total of 64 patients. In each cohort, 6 patients received QR-010 and 2 patients received placebo.
Click here to read the full press release.
Source: globenewswire.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to theĀ cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Ā